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Introduction {#s1}
============

Pituitary adenomas are neoplasms of the anterior pituitary lobe. They account for 15--20% of all the intracranial tumors [@pone.0109897-Heaney1] and approximately 16% of all the primary brain and central nervous system tumors [@pone.0109897-Dolecek1]. The hallmarks of pituitary tumors are hormonal dysfunction, i.e hormonal hypersecretion or hypopituitarism and local symptoms related to the tumor mass. Compression of neighboring structures may cause headaches and visual impairment [@pone.0109897-Asa1]. Pituitary adenomas are classified based on the pituitary cell of origin and the type of hormone secreted. The most common functional pituitary tumors hypersecrete prolactin (PRL) (40--45%). Patients with prolactinomas present with amenorrhea, infertility and galactorrhea in females, and infertility in males. Somatotropinomas hypersecrete growth hormone (GH) (20--25%), causing acromegaly with clinical features of enlarged extremities, coarse facial structures and comorbidities such as hypertension, cardiovascular disease and diabetes mellitus [@pone.0109897-Arafah1]. The rate of mortality associated to untreated acromegaly has been reported to be two to four times higher than that seen in the healthy population [@pone.0109897-Dekkers1], [@pone.0109897-Swearingen1]. In many cases, slow progression of the symptoms delays the diagnosis [@pone.0109897-Reid1]. Somatotropinoma during childhood or adolescence, before the growth of the long bones is complete, leads to gigantism. Tumors secreting adrenocorticotropic hormone (ACTH) (10--12%) cause Cushing's disease, which is characterized by hypercortisolism. The majority of the other adenomas are non-functioning (non-secreting) pituitary adenomas (NFPA) [@pone.0109897-Arafah1]. All in all, pituitary adenomas cause a heavy clinical burden due to increased morbidity and the treatment modalities involved, i.e neurosurgery, chronic medical therapies and radiotherapy.

Most pituitary adenomas are sporadic but it has been estimated that 5% of affected patients have a familial background [@pone.0109897-Tichomirowa1]. Pituitary adenomas occur as components of familial tumor syndromes such as multiple endocrine neoplasia type 1 (MEN1) [@pone.0109897-Larsson1], [@pone.0109897-Chandrasekharappa1], Carney's complex (CNC) [@pone.0109897-Casey1], [@pone.0109897-Kirschner1] and MEN4 [@pone.0109897-Pellegata1]. Furthermore, in 2006, Vierimaa *et al.* found that germline mutations in the *aryl hydrocarbon receptor interacting protein* (*AIP*) gene cause pituitary adenoma predisposition (PAP) [@pone.0109897-Vierimaa1]. *AIP* mutations are mostly associated with somatotropinomas (78%), although cases with prolactinomas, NFPAs and Cushing's syndrome have also been reported [@pone.0109897-Daly1], [@pone.0109897-Cazabat1]. The patients with *AIP* mutations are typically young (mean age at diagnosis 25 years) and do not necessary have a strong family history of the disease. *AIP* associated pituitary tumors are often large and invasive and resistant to the effects of available treatments, such as somatostatin analogues, which are used in acromegaly [@pone.0109897-Leontiou1]--[@pone.0109897-Beckers1]. Familial occurrence of pituitary tumors is also the main feature in familial isolated pituitary adenoma (FIPA) [@pone.0109897-Tichomirowa1], [@pone.0109897-Daly3]. Subsequently, it was found that *AIP* germline mutations explain 15--20% of FIPA families and 50% of families with isolated familial somatotropinomas (IFS) [@pone.0109897-Daly1]. Thus, the majority of FIPA families appear to be influenced by some other, as yet unidentified genes responsible for familiar clustering of pituitary tumors. Identification of new predisposing genes would enable earlier detection of pituitary adenomas and contribute to clinical management of patients.

The *stimulatory guanine nucleotide (GTP) binding protein alpha* (*GNAS*; encoding Gα~s~ subunit) has been found to be mutated in 30--40% of sporadic somatotropinomas. These somatic gain-of-function mutations lead to constitutive activation of cyclic adenosine monophosphate (cAMP) synthesis and increased proliferation through cAMP mediated mitogenic signaling [@pone.0109897-Vallar1]--[@pone.0109897-Gupta1]. Activating mutations on *GNAS* are also associated to McCune-Albright syndrome [@pone.0109897-Weinstein1], [@pone.0109897-Schwindinger1]. Along with well-established *GNAS* mutations, somatic mutations in other Gα family members, namely *GNAQ* and *GNA11*, have been linked to tumorigenesis in melanocytic neoplasms [@pone.0109897-VanRaamsdonk1], [@pone.0109897-VanRaamsdonk2].

We have recently demonstrated that *AIP* loss-of-function mutations predispose to pituitary tumorigenesis through defective inhibitory GTP binding protein (Gα~i~) signaling and consequent elevated intracellular cAMP concentrations [@pone.0109897-Tuominen1]. We found that Gα~i-2~ and Gα~i-3~ proteins are not capable of inhibiting cAMP synthesis during *AIP* deficiency and that Gα~i-2~ protein levels are significantly reduced in *AIP*-mutated somatotropinomas. As the AIP protein seems to be an essential regulator of Gα~i~ signaling, the possibility that inactivating germline mutations in *GNAI* loci (encoding Gα~i~ subunits) would predispose to pituitary adenomas prompted us to investigate the role of these genes in pituitary tumorigenesis. Here we sequenced all the coding exons of *GNAI1* ~,~ *GNAI2* and *GNAI3* in a set of young sporadic somatotropinoma patients and familial index cases, thus in patients with a disease phenotype similar to that observed in *AIP* mutation carriers.

Materials and Methods {#s2}
=====================

Gα~i~ immunohistochemistry {#s2a}
--------------------------

To investigate the expression of Gα~i~ proteins in human pituitary tumors, Gα~i-1~, Gα~i-2~ and Gα~i-3~ immunostainings were performed in four prolocatinomas, six somatotropinomas, three ACTH and four NFPA tumors. All tumors were *AIP* mutation negative. Antibodies used were mouse monoclonal antibody against Gα~i-1~ (SPM397, sc-56536, Santa Cruz, 1: 40), rabbit polyclonal antibody against Gα~i-2~ (T19, sc-7276, Santa Cruz, 1: 60) and mouse polyclonal antibody against Gα~i-3~ (H00002773-B01P, Abnova Corp. Taipei city, Taiwan, 1: 50). Anti-mouse/rabbit/rat secondary antibody, Poly-HRP-GAM/R/R (DPVB55HRP, Immunologic, Duiven, Netherlands) and DAB chromogen (Lab Vision Corporation, Fremont, CA, USA, Thermo Fisher Scientific, Watham, MA, USA) were used for detection. Immunostaining protocol was applied as described [@pone.0109897-Raitila1]. The staining intensities of Gαi proteins were scaled as negative (0), weak (1), moderate (2), or strong (3). The images were taken and edited by Leica DM LB microscope (Meyer Instruments, Houston, TX, USA), Olympus DP50 camera (Olympus Corporation, Tokyo, Japan) and Studio Lite software (Licor, Lincoln, NE, USA).

Patients {#s2b}
--------

This study included a set of 32 young sporadic GH-secreting pituitary adenoma cases in which three of the tumors were secreting both GH and PRL. Age at diagnosis for sporadic cases ranged from 14 to 56 years with a mean of 32 years ([Table 1](#pone-0109897-t001){ref-type="table"}). A majority of the tumors were macroadenomas. The second set of samples included 14 index cases with a familial history of pituitary adenomas ([Table 1](#pone-0109897-t001){ref-type="table"}). The hormones secreted by the tumors were GH (*n* = 11), PRL (*n* = 1), ACTH (*n* = 1) and NFPA (*n* = 1). All the patients had previously been sequenced negative for *AIP*. From familial cases 9/14 were earlier screened negative for large germline deletions of *AIP* [@pone.0109897-Georgitsi1]. The study and the consent procedures were approved by the Ethics Committee of the Hospital district of Helsinki and Uusimaa (HUS) (approval number: 408/13/03/03/2009) and the Institutional Review Board of the Department of Internal Medicine, General Hospital, Montebelluna (Treviso). Signed informed consent was obtained from all the study participants. In case of the minor/children, the consent was obtained from parent/guardian. Consents are stored and managed together with patient information in the central office/ambulatories where the access is restricted.

10.1371/journal.pone.0109897.t001

###### Patient information and variants detected in the coding regions of *GNAI* loci.

![](pone.0109897.t001){#pone-0109897-t001-1}

  Patient      Sex   Age at Dg   Age at Op   Origin    Clinical Dg   TumorSize   Affectedfamilymember(s)           *GNAI1*                 *GNAI2*                            *GNAI3*
  ----------- ----- ----------- ----------- --------- ------------- ----------- ------------------------- ------------------------- ---------------------- ----------------------------------------------
  **S1**        M       37          --        Spain        GH          Macro               --                        --                       --                                 --
  **S2**        M       40          --       Tunisia       GH          Macro               --                        --                       --                                 --
  **S3**        F       38          --       Finland       GH          Macro               --                        --                       --                                 --
  **S4**        M       14          --       Finland       GH          Macro               --                        --                       --                                 --
  **S5**        F       24          --        Italy      GH/PRL         NA                 --                        --                       --                                 --
  **S6**        F       24          --        Italy      GH/PRL        Macro               --                        --                       --                                 --
  **S7**        F       23          --        Italy        GH          Macro               --                        --                       --                                 --
  **S8**        M       22          --        Italy        GH           NA                 --                        --                       --                                 --
  **S9**        F       19          --        Italy        GH          Macro               --                        --                       --                                 --
  **S10**       F       17          --        Italy        GH          Macro               --                        --                       --                                 --
  **S11**       M       33          --        Italy        GH          Macro               --              c.468G\>GA(rs12721456)             --            c.105G\>GA(rs2230350) c.987G\>GA(rs61758987)
  **S12**       M       30          --        Italy        GH          Macro               --              c.468G\>GA(rs12721456)    c.138C\>CT(rs762707)                        --
  **S13**       F       37          --        Italy        GH          Macro               --              c.846T\>TC(rs10241877)             --                                 --
  **S14**       F       36          --        Italy        GH          Micro               --                        --                       --                                 --
  **S15**       F       33          --        Italy        GH          Macro               --                        --                       --                                 --
  **S16**       M       36          --        Italy        GH          Macro               --                        --                       --                                 --
  **S17**       M       23          --        Italy        GH          Macro               --                        --                       --                                 --
  **S18**       M       35          --        Italy        GH          Macro               --              c.846T\>TC(rs10241877)             --                                 --
  **S19**       F       32          --        Italy        GH          Macro               --                        --                       --                                 --
  **S20**       F       36          --        Italy        GH          Macro               --              c.468G\>GA(rs12721456)    c.138C\>CT(rs762707)                        --
  **S21**       M       39          --        Italy        GH          Macro               --                        --                       --                       (c.105G\>GA)rs2230350
  **S22**       M       38          --        Italy        GH          Micro               --              c.468G\>GA(rs12721456)             --                                 --
  **S23**       M       26          --       Finland       GH           NA                 --              c.846T\>TC (rs10241877)            --                                 --
  **S24**       F       40          --        Italy        GH           NA                 --                        --                       --                                 --
  **S25**       M       23          --       Finland     GH/PRL        Macro               --              c.846T\>TC(rs10241877)             --                                 --
  **S26**       F       43          --       Finland       GH           NA                 --              c.846T\>TC(rs10241877)             --                                 --
  **S27**       F       24          --       Finland       GH          Macro               --                        --                       --                                 --
  **S28**       F       39          --       Estonia       GH          Macro               --                        --                       --                                 --
  **S29**       M       40          --       Finland       GH           NA                 --                        --                       --                                 --
  **S30**       F       25          --        Italy        GH           NA                 --                        --                       --                                 --
  **S31**       M       56          --       Finland       GH           NA                 --              c.846T\>TC(rs10241877)             --                                 --
  **S32**       F       55          --       Finland       GH           NA                 --                        --                       --                                 --
  **F1**        F       40          --        Italy        GH          Micro          NFPP (father)                  --                       --                                 --
  **\*F2**      F       56          NA        Italy        GH           NA              GH (aunt)                    --                       --                                 --
  **\*F3**      M       56          NA        Italy       NFPA          NA             GH (mother)                   --                       --                                 --
  **\*F4**      F       NA          67        Italy       ACTH          NA              GH (son)                     --                       --                                 --
  **\*F5**      F       NA          36        Italy        PRL          NA              GH (aunt)                    --              c.138C\>CT(rs762707)                        --
  **\*F6**      F       NA          49        Italy        GH           NA           PRL (daughter)                  --                       --                                 --
  **\*F7**      M       42          NA        Italy        GH           NA             GH (cousin)                   --                       --                                 --
  **\*F8**      M       36          --       Finland       GH           NA             GH (uncle)          c.846T\>TC(rs10241877)             --                                 --
  **F9**        F       NA          59       Finland       GH           NA             PRL (niece)                   --                       --                       (c.105G\>GA)rs2230350
  **\*F10**     M       NA          44        Italy        GH           NA            NFPA (niece)         c.468G\>GA(rs12721456)             --                                 --
  **F11**       M       24          NA        Italy        GH           NA           GH/PRL (sister)                 --                       --                                 --
  **F12**       F       36          NA        Italy        GH           NA            GH (brother)                   --                       --                                 --
  **F13**       F       63          NA       Finland       GH           NA            ACTH (cousin)        c.846T\>TC(rs10241877)             --                                 --
  **\*F14**     M       40          NA       Finland       GH          Macro          PRL (cousin)                   --                       --                                 --

Dg: diagnosis, Op: operation, S: sporadic, F: familial, M: male, F: female, NA: not available, Micro: \<10 mm, Macro: \>10 mm. \* Screened negative for *AIP* germline deletions by MLPA.

Mutation Analysis on *GNAI* loci {#s2c}
--------------------------------

The coding regions of *GNAI1* (ENST00000442586 and ENST00000351004; Ensemble release 75), *GNAI2* (ENST00000422163, ENST00000451956 and ENST00000266027), and *GNAI3* (ENST00000369851) were amplified and sequenced from blood-derived DNA. Also intronic regions flanking the exons were included in the analyses. PCR was carried out by mixing 0.25 µl 20 mM of each primers ([Table 2](#pone-0109897-t002){ref-type="table"}), 5 ng/ul of DNA, 0.4 µl 40 mM of dNTP, 2.5 µl 10xPCR Buffer, and 0.1 µl AmpliTaq Gold DNA Polymerase (Invitrogen Life Science Technologies, Foster City, CA) in a final volume of 25 µl. PCR products were purified by using ExoSAP-IT PCR product cleanup reaction (Affymetrix, USB Products, CA, USA). DNA was sequenced by using BigDye v.3.1 sequencing chemistry and ABI3830x DNA sequencer (Applied Biosystems, Foster City, CA, USA). Sequences were analyzed with Mutation Surveyor software V4.0.8 (Soft-Genetics, State College, PA, USA).

10.1371/journal.pone.0109897.t002

###### Primer sequences, annealing temperatures and Ensembl transcripts for 23 amplicons of *GNAI* loci.

![](pone.0109897.t002){#pone-0109897-t002-2}

  Primer                 Sequence (5′ --3′)                 T~m~ (°C)               Trancript
  ----------------- ----------------------------- ----------------------------- -----------------
  Gα~i1~\_ex1_F          GGATTCCCCTGTGCTTGGA                   60                ENST00000442586
  Gα~i1~\_ex1_R          GTTTCCAAACGCCGAGGG                                     
  Gα~i1~\_ex2&3_F       CACACAGAGAGAGACTGGGTG                  60                ENST00000351004
  Gα~i1~\_ex2&3_R       GGTCCTGATAGTTGACAAGCC                                   
  Gα~i1~\_ex4_F          AAGGAAGTTCGCTATTGCC                   60                ENST00000351004
  Gα~i1~\_ex4_R         AATGTGTCAGCCAATTCTGC                                    
  Gα~i1~\_ex5_F        GTTTTGGATGATCTTTATTGGC                  60                ENST00000351004
  Gα~i1~\_ex5_R        TCTCCCAAACATTCTTTTGTCC                                   
  Gα~i1~\_ex6_F        CCCATAAAGTCCTTCTCTCCTTC     62×1, 61×1, 60×2, 59×2,58×2   ENST00000351004
  Gα~i1~\_ex6_R         CTTGGCAACACCTTCAGCTC                                    
  Gα~i1~\_ex7_F         TGTTCTGAAATGGCAGAAATG                  60                ENST00000351004
  Gα~i1~\_ex7_R         CTGAATTCTTGCCTTAGGGG                                    
  Gα~i1~\_ex8_F       GGAGTCCATGAATGAAACTGTATG                 60                ENST00000351004
  Gα~i1~\_ex8_R         TTTGGTCAAGTCCCAGATGC                                    
  Gα~i2~\_ex1c_F        TCACCCACATCACCGTCTAA                   59                ENST00000422163
  Gα~i2~\_ex1c_R         ACGCGTCCTCTTGCAACTA                                    
  Gα~i2~\_ex1d_F        CGCTGTCCATTGCTCTTCAT                   60                ENST00000451956
  Gα~i2~\_ex1d_R        GCACATGTGAGCATTCAGGT                                    
  Gα~i2~\_ex2_F         AGCTGAAGTGTGACGCTGTG                   58                ENST00000266027
  Gα~i2~\_ex2_R          CTTGGCCAGCCATGAAGG                                     
  Gα~i2~\_ex3&4_F       ATGTGAGAACAGGGTGGCTC                   58                ENST00000266027
  Gα~i2~\_ex3&4_R      GGATTCCCTAGGATGAGACTTG                                   
  Gα~i2~\_ex5_F         CCAAGAATACCCTAGCCTGG                   60                ENST00000266027
  Gα~i2~\_ex5_R          GCAAAGACCAGCAGTGTCC                                    
  Gα~i2~\_ex6_F        CTACCTGAACGACCTGGAGCGTA                 58                ENST00000266027
  Gα~i2~\_ex6_R         CTCTGCTACCCCAGAGGCTG                                    
  Gα~i2~\_ex7&8_F       AAATGGGGTAGAAAGCCTCC                   58                ENST00000266027
  Gα~i2~\_ex7&8_R       TGGTCACCATAGGCTACTTGG                                   
  Gα~i2~\_ex9_F         CTTGCTGCACACGTAGGATG                   58                ENST00000266027
  Gα~i2~\_ex9_R          CGCTTAGTTCTTCCCCAGC                                    
  Gα~i2~\_ex9b_F        GTCCACCTGCTCATTCTCGT                   60                ENST00000266027
  Gα~i2~\_ex9b_R        TGGAACCCAATTCTGTGGAG                                    
  Gα~i3~\_ex1_F          GCAGTTTCCGTGGTGTGAG                   58                ENST00000369851
  Gα~i3~\_ex1_R          GTTCAGGCCTTCCAAGCG                                     
  Gα~i3~\_ex2&3_F       TAGGACCCGTGGTTTTCATC                   60                ENST00000369851
  Gα~i3~\_ex2&3_R      TTGTTGCTTAAATTCATTTCCC                                   
  Gα~i3~\_ex4_F         CTGGCCTGTCAGAAAAGGTC                   60                ENST00000369851
  Gα~i3~\_ex4_R        AAACATTTCCTTAAGTGGGGAC                                   
  Gα~i3~\_ex5_F         TTTGCTATGCACATGGTTGG                   60                ENST00000369851
  Gα~i3~\_ex5_R       AAATTTTACCCTGATTAAGAGATGG                                 
  Gα~i3~\_ex6_F        CATTTCAGTTTAGGGGAAGGTG                  60                ENST00000369851
  Gα~i3~\_ex6_R        TTATTTTCCATTTCCTGGCTAC                                   
  Gα~i3~\_ex7_F         TGAATGCCATTTAGTGCTGC                   60                ENST00000369851
  Gα~i3~\_ex7_R        GCCACTACCACTGAATACTCTCC                                  
  Gα~i3\_~ex8_F         TTGGGTTATGTTCCCTCTCC                   60                ENST00000369851
  Gα~i3~\_ex8_R      CAAGAGACATCACTGTAGCACTATAAC                                

T~m~: annealing temperature.

Results {#s3}
=======

Gα~i~ immunohistochemistry {#s3a}
--------------------------

To examine the Gα~i~ protein expressions in human pituitary adenomas, Gα~i-1,~ Gα~i-2,~ Gα~i-3~ expressions were immunohistochemically (IHC) analyzed in *AIP* mutation negative somatotropinomas, prolactinomas, NFPA and ACTH tumors. Weak and speckled cytoplasmic expression of Gα~i-1~ was detected in GH- (mean±SD; 0.8±0.4) and PRL- (1±0.8) secreting tumors, whereas NFPA (1.8±0.5) and ACTH (1.7±0.6) tumors showed weak to moderate cytoplasmic expression ([Figure 1](#pone-0109897-g001){ref-type="fig"}). Consistent with the earlier observation in human GH-secreting tumors [@pone.0109897-Tuominen1], Gα~i-2~ was prominently expressed in the cytoplasm of the somatotropinomas (2.8±0.4). Prolactinomas displayed moderate to strong expression of Gα~i-2~ (2.5±0.6). NFPA (1.8±0.5) and ACTH (1.7±0.6) adenomas showed moderate cytoplasmic and occasional nuclear Gα~i-2~ staining. All tumor types displayed moderate cytoplasmic expression of Gα~i-3~ (GH: 2.3±0.5, PRL: 2±0.8, ACTH: 1.6±0.6, NFPA: 1.8±0.5). Weak to moderate nuclear Gα~i-3~ staining was also observed in all tumor types (GH: 1.3±0.8, PRL: 0.8±0.5, ACTH: 1.3±0.6, NFPA: 1.5±0.6).

![Gα~i-1,~ Gα~i-2~, and Gα~i-3~ protein expressions in GH, PRL, ACTH and non-functioning (NFPA) pituitary adenomas.\
Scale bar = 20 µm.](pone.0109897.g001){#pone-0109897-g001}

*GNAI* loci mutation analysis {#s3b}
-----------------------------

All the *GNAI* coding exons (23 amplicons per sample) were successfully sequenced and analyzed in 32 young sporadic somatotropinoma and 14 index familial cases ([Table 1](#pone-0109897-t001){ref-type="table"}). In *GNAI1*, earlier reported synonymous heterozygous variations were detected in exon 6 (rs12721456/5 samples) and in exon 7 (rs10241877/8 samples). In *GNAI2*, one reported heterozygous and synonymous variation was found in exon 4 (rs762707/3 samples). Also in *GNAI3,* only previously observed heterozygous synonymous variations were detected in exon 1 (rs2230350/3 samples) and exon 8 (rs61758987/1 sample). None of these variants modified amino acid sequence, indicating the polymorphic nature of these changes. Additionally, several reported and unreported variations were observed in intronic regions ([Table S1](#pone.0109897.s001){ref-type="supplementary-material"}). All the intronic variants located outside of the splice site consensus sequences and are thus not assumed to affect splicing events.

Discussion {#s4}
==========

Many G proteins have been linked to tumor development, starting with the discovery that somatic gain-of-function mutations of codons 201 and 227 in the *GNAS* gene are responsible in one third of the sporadic somatotropinomas with elevated cAMP levels [@pone.0109897-Landis1], [@pone.0109897-Lyons1]. Activating *GNAS* hot-spot mutations have been detected in many other tumor types. For instance, biliary tract, thyroid, pancreatic, colon, and testis tumors are common targets of somatic *GNAS* mutations. Additionally, activating somatic hotspot mutations have been reported in *GNAQ* (Gα~q~) and *GNA11* (Gα~11~) genes in melanomas and meningeal tumors [@pone.0109897-OHayre1]. Somatic mutations in other Gα subunit genes have been detected, albeit in a low frequency.

Proteins of the inhibitory Gα subfamily, Gα~i~/Gα~o~, mediate several cellular and metabolic functions [@pone.0109897-Wettschureck1]--[@pone.0109897-Epstein1]. Unlike the Gα~o~, Gα~i-1~, Gα~i-2~ and Gα~i-3~ subunits are involved in the hormonal inhibition of adenylate cyclase (AC) activity with subsequent decrease of intracellular cAMP levels [@pone.0109897-Kobayashi1], [@pone.0109897-Peverelli1]. Previous studies have been focusing on screening *GNAI2* somatic hot-spot mutations (termed *gip2* oncogene) in codons 179 and 205. Somatic *gip2* mutations have been found in ovarian, adrenal, ACTH and NFPA tumors [@pone.0109897-Lyons1], [@pone.0109897-Williamson1], [@pone.0109897-Williamson2] **.** However, other studies have failed to confirm these initial findings [@pone.0109897-Tordjman1]--[@pone.0109897-Shen1]. Although isolated somatic mutations of *GNAI* genes have also been observed in next-generation sequencing efforts, further experiments are needed to validate the existence and relevance of these findings [@pone.0109897-Forbes1], [@pone.0109897-Fu1].

In our original study, we found that *AIP* deficiency is associated in pituitary tumorigenesis via reduced Gα~i~ signaling followed by elevated cAMP concentrations [@pone.0109897-Tuominen1]. In the current study, we searched for germline mutations in *GNAI* loci in pituitary adenoma patients compatible with the *AIP* phenotype; young patients with somatotropinoma and familial index cases ([Table 1](#pone-0109897-t001){ref-type="table"}). Also protein expressions of Gα~i-1~, Gα~i-2~ and Gα~i-3~ were examined in human GH-, PRL-, ACTH- and non-secreting (NFPA) pituitary adenomas. We have earlier shown that Gα~i-2~ and Gα~i-3~ proteins are expressed in human somatotropinomas [@pone.0109897-Tuominen1]. Here we observed that also the Gα~i-1~ protein, although at low levels, is present in GH-secreting pituitary adenomas. Moreover, immunoreactions against all three Gα~i~ proteins were detected in human prolactinomas, ACTH and NFPA tumors ([Figure 1](#pone-0109897-g001){ref-type="fig"}), suggesting a biological role of all these proteins in these tumor types as well.

We screened for germline mutations in the *GNAI* loci in sporadic somatotropinoma patients (*n* = 32) and familial index cases (*n* = 14) characterized by the *AIP* phenotype ([Table 1](#pone-0109897-t001){ref-type="table"}). No pathogenic mutations were observed in any of the patients studied. All the detected variants were either known polymorphisms or located in intronic regions. Although certain intronic variants may cause impaired splicing, the observed variants were not proximal to known splice sites. We acknowledge that the sample size in the present study is insufficient to draw a definite conclusion of the involvement of *GNAI* germline mutations in genetic predisposition of pituitary tumors. Moreover, due to the small sample size there is no adequate power to detect possible associations between the observed variant alleles and a pituitary tumor phenotype.

To our knowledge, this is the first time that all the coding exons of *GNAI1*, *GNAI2* and *GNAI3* have been sequenced to detect germline loss-of-function mutations in a set of selected pituitary adenoma patients. All in all, our sequencing results suggest that germline mutations of the *GNAI* loci seem not to be associated to, or are rare in familial pituitary tumorigenesis. However, a larger set of samples, somatic mutation screenings, copy number profiling and additional cellular works would provide a more comprehensive result of the role of *GNAI* genes in pituitary tumorigenesis.
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